Bluebird bio Inc [BLUE] stock is trading at $1.25, up 5.93%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BLUE shares have gain 15.74% over the last week, with a monthly amount glided 16.82%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, January 2024, bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook. In a post published today on Yahoo Finance, Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives.
From an analyst’s perspective:
Bluebird bio Inc [NASDAQ: BLUE] stock has seen the most recent analyst activity on December 11, 2023, when HSBC Securities downgraded its rating to a Reduce. Previously, Morgan Stanley upgraded its rating to Equal-Weight on December 08, 2023, and elevated its price target to $7. On October 17, 2023, Cantor Fitzgerald initiated with a Neutral rating. HSBC Securities started tracking the stock assigning a Buy rating and suggested a price target of $4.21 on September 06, 2023. BofA Securities upgraded its rating to a Buy and raised its price target to $10 on July 19, 2023. Barclays upgraded its rating to Overweight for this stock on June 01, 2023, and upped its price target to $8. In a note dated April 28, 2023, JP Morgan initiated an Overweight rating and provided a target price of $7 on this stock.
Bluebird bio Inc [BLUE] stock has fluctuated between $0.88 and $5.53 over the past year. Currently, Wall Street analysts expect the stock to reach $14.13 within the next 12 months. Bluebird bio Inc [NASDAQ: BLUE] shares were valued at $1.25 at the most recent close of the market. An investor can expect a potential return of 1030.4% based on the average BLUE price forecast.
Analyzing the BLUE fundamentals
Bluebird bio Inc [NASDAQ:BLUE] reported sales of 21.73M for the trailing twelve months, which represents a growth of 17353.52%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1742 points at the first support level, and at 1.0984 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3229, and for the 2nd resistance point, it is at 1.3958.
Ratios To Look Out For
For context, Bluebird bio Inc’s Current Ratio is 1.55. Further, the Quick Ratio stands at 1.42, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 11.09, the price to book ratio is 0.60.
Transactions by insiders
Recent insider trading involved Vittiglio Joseph, Chief Business & Legal Officer, that happened on Feb 05 when 5217.0 shares were sold., Klima Thomas J completed a deal on Feb 05 to sell 2714.0 shares. Meanwhile, President and CEO Obenshain Andrew sold 1879.0 shares on Feb 05.
